Barclays’s Ligand Pharmaceuticals LGND Stock Holding History

Barclays’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-641	Closed	-$46K	–	6939
2019 Q2	$46K	Hold	641	–	–	﹤0.01%	6137
2019 Q1	$50K	Buy	+641	New	+$48.6K	﹤0.01%	5872
2017 Q2	–	Sell	-50,334	Closed	-$3.32M	–	6793
2017 Q1	$3.32M	Hold	50,334	–	–	﹤0.01%	1628
2016 Q4	$3.19M	Hold	50,334	–	–	﹤0.01%	1734
2016 Q3	$3.21M	Buy	+50,334	New	+$3.7M	﹤0.01%	1620
2014 Q4	–	Sell	-6,252	Closed	-$179K	–	7454
2014 Q3	$179K	Buy	+6,252	New	+$208K	﹤0.01%	4840
2014 Q2	–	Sell	-197,810	Closed	-$8.27M	–	7711
2014 Q1	$8.27M	Buy	+197,810	New	+$8.25M	0.01%	1289

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's LGND Position: Q2 2026 in Review

Barclays increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q2 2026, buying an estimated $169K and bringing the position to 6,727 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

Barclays first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $39.7M in Q3 2018. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Barclays held 6,727 shares of Ligand Pharmaceuticals worth $2.13M as of Q2 2026.
Barclays bought 719 Ligand Pharmaceuticals shares in Q2 2026, an estimated $169K.
Ligand Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2308 holding.
Barclays first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Barclays's Ligand Pharmaceuticals position peaked at $39.7M in Q3 2018.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.